• Home
  • Journal
  • Public Companies
  • PharmaCyte Biotech to Offer COVID-19 Testing While Creating Revenue Stream for Pancreatic Cancer Program

PharmaCyte Biotech to Offer COVID-19 Testing While Creating Revenue Stream for Pancreatic Cancer Program

NEW YORK, NY, April 13, 2020 (GLOBE NEWSWIRE) — PharmaCyte Biotech (OTCQB: PMCB) is a California-based biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, and while it continues to focus on submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for its treatment for locally advanced, inoperable pancreatic cancer, it has also seized an opportunity to offer testing kits for the coronavirus disease (COVID-19).  According to the company’s investor relations, this opportunity would create a revenue stream for its pancreatic cancer program.The virus—known as “Severe Acute Respiratory Syndrome Coronavirus 2” or “SARS-CoV-2,” causes the disease COVID-19, which has become a global pandemic that will require testing for the foreseeable future, including after a cure can be developed and approved for the disease.  To that end, through relationships that PharmaCyte has developed in Hong Kong, it has partnered with Hai Kang Life Corporation (Hai Kang) to deliver a testing solution that could offer a much more accurate test than is currently being used globally.The first step is to apply to the U.S. FDA for Emergency Use Authorization and prove that the test manufactured by Hai Kang works for the purposes of detecting the SARS-CoV-2 virus.  It’s a process that can take as little as a few weeks.  PharmaCyte’s investor relations said of its partnership with Hai Kang, “We will be able to help with the shortage of accurate diagnostic kits.  If we obtain approval, it should provide an immediate and material stream of revenue to us to help fund our other endeavors, while at the same time, helping a world in dire need for the product we are trying to get approved for use in the clinic.”And it appears that PharmaCyte has partnered with the absolute best as Hai Kang’s founder and current chairman, Professor Albert Cheung-Hoi Yu, Ph.D., developed a test that he reported just last month is 10 times more sensitive than the other tests being used to detect the virus. As a matter of fact, it’s a test that was published in The New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJM200404083501523), after it proved to be more sensitive, reliable and accurate in detecting the SARS-CoV (SARS) virus during the 2002-2003 outbreak in China.  Hai Kang’s test for SARS-CoV-2 was developed when Professor Yu and his team re-examined the same technology and methods that were used successfully to develop the test for the SARS virus and found that the test is also applicable to the new coronavirus.There are two main types of tests being used to detect SARS-CoV-2: molecular and serological.  In acute respiratory infections like COVID-19, molecular tests, like the ones used by both the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), are routinely used to detect the presence of viral genetic material in a sample.  The specific technique that is used is called Reverse Transcription Polymerase Chain Reaction, or RT-PCR, where genetic material from a patient’s sample is copied and then compared to the genetic sequence of the virus that you’re trying to detect.  And specifically related to COVID-19, these tests detect the genetic signature (RNA) of the SARS-CoV-2 virus in swab samples.However, with every test, there’s a “limit” at which you can still detect a signal. A negative result with the molecular test means that the virus that causes COVID-19 was not found in the sample “above the limit” of detection, but it is still possible to have very low levels of the virus in the body; therefore, these tests will produce a “false negative” because they need a larger sample of genetic material to detect the virus.Hai Kang says that its testing kit, on the other hand, eliminates the false negatives by improving upon the RT-PCR tests with its own Enhanced Fluorescent Real-Time Reverse Transcription-Polymerase Chain Reaction (ERT-PCR) tests, which are so sensitive that they only require a minimum sample to detect the virus.  The company states that the RT-PCR detection technology being used around the world must use 50 to 100 viral genes for testing, while Hai Kang’s ERT-PCR test only needs to use one viral gene to detect the virus.Professor Yu, who is also the Chairman of the Hong Kong Biotechnology Association, told reporters last month that after comparing his company’s testing kits for SARS-CoV-2 to all other RT-PCR technologies, “Our method is the most sensitive method in the world.”To learn more about PharmaCyte Biotech visit: https://www.PharmaCyte.com and to learn more about Hai Kang Life visit: https://www.haikanglife.com/index.php/en/
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is developing the use of genetically modified liver cells and stem cells, as well beta islet cells, to treat diabetes. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.About Stock Market Media GroupStock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with press releases, research reports, corporate videos, radio-style CEO interviews and feature news articles.This article was written based upon publicly available information. Stock Market Media Group may, from time to time, include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB’s filings and disclosures. We also recommend, as a general rule, that before investing in any securities, you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.  We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about PMCB are not a recommendation to buy or sell a security.Stock Market Media Group and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company’s profile. Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment.  Under the Securities Act of 1933, Section 17(b), Stock Market Media Group discloses that it expects to be remunerated fifteen thousand dollars monthly from September 2019 to September 2020, paid for by a third party via bank wire, to produce content related to PharmaCyte. This article is the opinion of Stock Market Media Group and was written based upon publicly available information and interviews conducted by SMMG.Stock Market Media Group does not own any shares in PharmaCyte and never accepts compensation in free-trading shares for its marketing services of the company being profiled, however third parties that might have compensated Stock Market Media Group may hold free-trading shares of the company being profiled and could very well be selling, holding or buying shares of the company’s stock at the same time the content is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the company’s profile, our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.For more information: www.stockmarketmediagroup.comContact:Stock Market Media Group


Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.